<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328834</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PRGLN-003</org_study_id>
    <nct_id>NCT01328834</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release
      Capsules (ADVAGRAF) treatment for the induction therapy of refractory lupus nephritis (LN).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (complete or partial remission)</measure>
    <time_frame>6 months after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of proteinuria</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLEDAI scores</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
    <description>SLEDAI:Systemic Lupus Erythematosus Disease Activity Index (Bombardier et al, 1992).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
    <description>Adverse events, including infections, transient increases in serum creatinine, gastrointestinal complaints, liver function disorder and glucose intolerance, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of renal function</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephritis, Lupus</condition>
  <arm_group>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Sustained-release Capsules (ADVAGRAF)</intervention_name>
    <description>Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.</description>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <other_name>ADVAGRAF: Tacrolimus Sustained-release Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex, 14-65 years of age;

          2. Diagnosis of SLE according to the ACR criteria (1997);

          3. Kidney biopsy within the 6 months prior to study with a histologic diagnosis (ISN/RPS
             2003 classification of LN) class IV, V, V+ III, V+ IV;

          4. Usage of intravenous pulse cyclophosphamide for more than 3 times or immunosuppression
             therapy (AZA, MMF, oral cyclophosphamide, ect) for more than 6 months;

          5. proteinuria &gt; 1g/24hr or Scr &gt; 1.3 mg/dl or active urinary sediment (erythrocyte cast,
             &gt; 5 WBC/high power field (hpf) (excluding infection), &gt; 5 RBC/hpf);

          6. Provision of written informed consent by subject or guardian

        Exclusion Criteria:

          1. Inability or unwillingness to provide written informed consent ;

          2. Usage of immunosuppression therapy (MMF, CTX, CysA, MTX etc) for more than 1 week
             within 1 month or intravenous MP Pulse treatment prior to entry;

          3. Scr &gt; 4mg/dl (354umol/L);

          4. Needing pulse intravenous MP or intravenous immunoglobulin;

          5. Lupus encephalopathy;

          6. Diagnosed DM; Malignant tumors (except fully cured basal cell carcinoma);

          7. History of significant gastrointestinal disorders (e.g. active peptic ulcer disease or
             pancreatitis) within 3 month prior to enter this study;

          8. Known hypersensitivity or contraindication to tacrolimus, corticosteroids

          9. Any Active systemic infection or history of serious infection within one month of
             entry or known infection with HIV, hepatitis B, or hepatitis C;

         10. Participation in another clinic trial and/or receipt of investigational drugs within 4
             weeks prior to screening;

         11. Pregnancy, nursing or use of a non-reliable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Xueqing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University IRB</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Xueqing Yu</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>Nephritis, Lupus</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

